Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1997-5-8
|
| pubmed:abstractText |
Herpes simplex virus type 1 (HSV-1) represents a promising new viral vector capable of efficient transduction of myofibers in vivo. Here we report on the use of a replication-defective HSV-1 mutant vector (DZ) deleted for the essential immediate early (IE) gene ICP4 for studies of reporter gene transfer and expression following direct inoculation of mouse skeletal muscle. The recombinant vector was engineered to contain the Escherichia coli lacZ gene under transcriptional control of the strong human cytomegalovirus (HCMV) IE promoter. The effect of vector cytotoxicity on the durability of transgene expression following infection of muscle cells in culture and myofibers in vivo revealed that this first-generation HSV vector was cytopathic, limiting the persistence of vector-transduced cells. UV irradiation of vector preparations reduced viral cytotoxicity for myoblasts in culture without reducing significantly beta-galactosidase production. Moreover, muscle cell viability and the durability of transgene expression was enhanced by several days following UV inactivated-vector infection in vivo. Nevertheless, the viral DNA was subsequently lost from vector-inoculated muscle tissue within 2 weeks. This observation indicated that vector toxicity alone did not account for the lack of persistent transgene expression. Longer-term vector transduction and transgene expression was observed, however, following inoculation of immunodeficient SCID mice, indicating that host immunocompetence played an important role in determining the duration of transgene expression in animals. To support this hypothesis, cells expressing CD4 and CD8 antigens have been found in the HSV-1 injected muscle of immunocompetent mice. These data demonstrated that both vector toxicity and vector-induced immunity are significant obstacles to the use of HSV-1 vectors for muscle gene transfer. These impediments must be overcome to further develop HSV vectors for muscle gene therapy applications.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1043-0342
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
8
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
439-52
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9054519-Animals,
pubmed-meshheading:9054519-DNA, Viral,
pubmed-meshheading:9054519-Defective Viruses,
pubmed-meshheading:9054519-Escherichia coli,
pubmed-meshheading:9054519-Gene Expression Regulation, Bacterial,
pubmed-meshheading:9054519-Gene Therapy,
pubmed-meshheading:9054519-Genes, Immediate-Early,
pubmed-meshheading:9054519-Genes, Reporter,
pubmed-meshheading:9054519-Genetic Vectors,
pubmed-meshheading:9054519-Herpesvirus 1, Human,
pubmed-meshheading:9054519-Humans,
pubmed-meshheading:9054519-Lac Operon,
pubmed-meshheading:9054519-Mice,
pubmed-meshheading:9054519-Mice, SCID,
pubmed-meshheading:9054519-Muscle, Skeletal,
pubmed-meshheading:9054519-Rats,
pubmed-meshheading:9054519-Transfection,
pubmed-meshheading:9054519-Transgenes
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
LacZ gene transfer to skeletal muscle using a replication-defective herpes simplex virus type 1 mutant vector.
|
| pubmed:affiliation |
Rangos Research Center in Musculoskeletal Research Center (MRSC) of the Department of Orthopaedic Surgery, University of Pittsburgh, School of Medicine, PA 15213, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|